JP2010530356A - 急性伝染hivエンベロープ・サイン - Google Patents

急性伝染hivエンベロープ・サイン Download PDF

Info

Publication number
JP2010530356A
JP2010530356A JP2010500974A JP2010500974A JP2010530356A JP 2010530356 A JP2010530356 A JP 2010530356A JP 2010500974 A JP2010500974 A JP 2010500974A JP 2010500974 A JP2010500974 A JP 2010500974A JP 2010530356 A JP2010530356 A JP 2010530356A
Authority
JP
Japan
Prior art keywords
hiv
env
infectious
sequence signature
consensus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010500974A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010530356A5 (cg-RX-API-DMAC7.html
Inventor
ヘインズ,バートン・エフ
コーバー,ベッテ・ティー
ハン,ベアトリス・エイチ
バッタチャルヤ,タンモイ
ナナカラン,ナナ・エス
ガオ,フェン
スワンストロム,ロン
ショー,ジョージ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Duke University
Original Assignee
University of California
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, Duke University filed Critical University of California
Publication of JP2010530356A publication Critical patent/JP2010530356A/ja
Publication of JP2010530356A5 publication Critical patent/JP2010530356A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2010500974A 2007-03-27 2008-03-27 急性伝染hivエンベロープ・サイン Pending JP2010530356A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90725907P 2007-03-27 2007-03-27
PCT/US2008/003965 WO2008118470A2 (en) 2007-03-27 2008-03-27 Acute transmitted hiv envelope signatures

Publications (2)

Publication Number Publication Date
JP2010530356A true JP2010530356A (ja) 2010-09-09
JP2010530356A5 JP2010530356A5 (cg-RX-API-DMAC7.html) 2011-05-12

Family

ID=39789201

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010500974A Pending JP2010530356A (ja) 2007-03-27 2008-03-27 急性伝染hivエンベロープ・サイン

Country Status (7)

Country Link
US (1) US20100104596A1 (cg-RX-API-DMAC7.html)
EP (1) EP2129395A4 (cg-RX-API-DMAC7.html)
JP (1) JP2010530356A (cg-RX-API-DMAC7.html)
CN (1) CN101969997A (cg-RX-API-DMAC7.html)
AU (1) AU2008231306A1 (cg-RX-API-DMAC7.html)
CA (1) CA2682206A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008118470A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2358757T3 (pl) 2008-11-18 2019-02-28 Beth Israel Deaconess Medical Center Szczepionki antywirusowe o ulepszonej immunogenności komórkowej
US20130177583A1 (en) * 2010-03-03 2013-07-11 Duke University Molecular clone of hiv-1
WO2011126576A2 (en) * 2010-04-09 2011-10-13 Duke University Genetic signatures in the envelope glycoprotein of hiv-1
EP3526236B1 (en) 2016-10-17 2025-12-10 Beth Israel Deaconess Medical Center, Inc. Signature-based human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005035555A1 (en) * 2003-10-10 2005-04-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv/siv env chimeras that promote trimerization and maintain targets of neutralizing antibodies
JP2006519160A (ja) * 2002-10-03 2006-08-24 ステイト リサーチ センター オブ ビロロジイ アンド バイオテクノロジー “ベクター” 抗原性ペプチド
JP2007505624A (ja) * 2003-09-17 2007-03-15 デューク・ユニバーシティー コンセンサス/先祖免疫原

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6585979B1 (en) * 1996-07-08 2003-07-01 Genentech, Inc. HIV envelope polypeptides and immunogenic composition
US20030215793A1 (en) * 2002-01-17 2003-11-20 Hahn Beatrice H. Complete genome sequence of a simian immunodeficiency virus from a wild chimpanzee
DE10343901A1 (de) * 2003-09-19 2005-04-14 Basf Ag Amidgruppenhaltige Ethylenterpolymere und ihre Verwendung

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006519160A (ja) * 2002-10-03 2006-08-24 ステイト リサーチ センター オブ ビロロジイ アンド バイオテクノロジー “ベクター” 抗原性ペプチド
JP2007505624A (ja) * 2003-09-17 2007-03-15 デューク・ユニバーシティー コンセンサス/先祖免疫原
WO2005035555A1 (en) * 2003-10-10 2005-04-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv/siv env chimeras that promote trimerization and maintain targets of neutralizing antibodies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6012069084; Vaccine, Vol.21 p.3301-3306 (2003) *
JPN6012069085; Virology, Vol.348 p.437-448 (2006) *
JPN6012069086; GenBank Acession No.Q3ZLH1 (28-NOV-2006)(http://www.ncbi.nlm.nih.gov/protein/q3zlh1) *
JPN6012069087; Science, Vol.296 p.2354-2360 (2002) *

Also Published As

Publication number Publication date
CN101969997A (zh) 2011-02-09
EP2129395A2 (en) 2009-12-09
AU2008231306A1 (en) 2008-10-02
CA2682206A1 (en) 2008-10-02
WO2008118470A2 (en) 2008-10-02
US20100104596A1 (en) 2010-04-29
EP2129395A4 (en) 2012-05-09
WO2008118470A3 (en) 2010-03-11

Similar Documents

Publication Publication Date Title
JP6165612B2 (ja) コンセンサス/先祖免疫原
Steckbeck et al. C-terminal tail of human immunodeficiency virus gp41: functionally rich and structurally enigmatic
Burgers et al. Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial
Hanke et al. Construction and immunogenicity in a prime–boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine
van Diepen et al. Prime-boost immunizations with DNA, modified vaccinia virus Ankara, and protein-based vaccines elicit robust HIV-1 tier 2 neutralizing antibodies against the CAP256 superinfecting virus
JP2011530309A (ja) 多価ワクチン
Bailey An assessment of the role of chimpanzees in AIDS vaccine research
Chakrabarti et al. Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate
US8916174B2 (en) HIV DNA vaccine regulated by a caev-derived promoter
EP3119890A1 (en) Swarm immunization with envelopes from ch505
Verrier et al. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates
AU2015240883B2 (en) Compositions comprising CH848 envelopes and uses thereof
US8765140B2 (en) DNA vaccine compositions with HIV/SIV gene modifications
US20100104596A1 (en) Acutte transmitted hiv envelope signatures
Boberg et al. Vaccination against drug resistance in HIV infection
HK1153677A (en) Acute transmitted hiv envelope signatures
US20170107260A1 (en) Mosaic hiv-1 sequences and uses thereof
WO2017152144A1 (en) Swarm immunization with envelopes from ch505
WO2016172070A1 (en) Swarm immunization with envelopes from ch505
MXPA06002993A (en) Dna vaccine compositions and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110325

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130612